New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Ocugen

Contributing Author

Recent Articles by Ocugen

Oct-02	Ocugen to Present at Industry and Investor Conferences in October 2025 OCGN GlobeNewswire
Sep-15	Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea OCGN GlobeNewswire
Sep-02	Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025 OCGN GlobeNewswire
Aug-13	Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST-Modifier Gene Therapy for Stargardt Disease OCGN GlobeNewswire
Aug-12	Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants OCGN GlobeNewswire
Aug-08	Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants OCGN GlobeNewswire
Aug-01	Ocugen Provides Business Update with Second Quarter 2025 Financial Results OCGN GlobeNewswire
Jul-21	Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team OCGN GlobeNewswire
Jul-18	Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST-Novel Modifier Gene Therapy Candidate for Stargardt Disease OCGN GlobeNewswire
Jul-17	Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results OCGN GlobeNewswire
Jun-23	Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases OCGN GlobeNewswire
Jun-16	Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST-Modifier Gene Therapy Candidate for Stargardt Disease OCGN GlobeNewswire
Jun-11	Ocugen To Present at BIO International Convention 2025 OCGN GlobeNewswire
Jun-05	Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea OCGN GlobeNewswire
May-27	Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST-Modifier Gene Therapy for the Treatment of Stargardt Disease OCGN GlobeNewswire
May-09	Ocugen Provides Business Update with First Quarter 2025 Financial Results OCGN GlobeNewswire
May-02	Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results OCGN GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.